ProPhase Labs, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
ProPhase Labs, Inc. (PRPH) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $10.00 per share as of 2023-01-12, per its 10-K filed 2025-04-01.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2025-04-01
- 2023-01-12: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $10.00.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2023-01-12 | $10.00 10-K · filed 2025-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |